AIT Therapeutics, Inc. (AITB) EPS Estimated At $-0.22

August 9, 2018 - By Jack Shaw

Analysts expect AIT Therapeutics, Inc. (OTCMKTS:AITB) to report $-0.22 EPS on August, 14 before the open.They anticipate $0.24 EPS change or 52.17 % from last quarter’s $-0.46 EPS. After having $0.14 EPS previously, AIT Therapeutics, Inc.’s analysts see -257.14 % EPS growth. It closed at $3.45 lastly. It is down 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company has market cap of $29.00 million. The company's pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis , cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It currently has negative earnings. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.